Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medistem, a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases, has modified an existing license agreement with the Institute for Cellular Medicine.
Subscribe to our email newsletter
Under the modified agreement, Medistem will receive $1 million cash and the return of 560,000 shares of Medistem common stock (valued at $700,000 based on the closing price on the date of the transaction).
In exchange, the territory of the license agreement is expanded, Medistem will no longer receive an ongoing royalty stream from the Institute for Cellular Medicine (ICM), and all existing loans and royalties due from ICM are satisfied. Medistem estimates that the value of the consideration received exceeds the value of existing amounts due by over $900,000.
Steve Rivers, CFO of Medistem, said: “Our previous relationship with ICM was success-based, and therefore presented economic uncertainty. The new agreement provides us immediate liquidity and reduces our dependence on revenue streams that are beyond our control.”